INCB161734
Sponsors
Incyte Corp., Incyte Corporation
Conditions
Healthy ParticipantsHepatic InsufficiencyKidney DiseasesLiver DiseasesPancreatic Ductal AdenocarcinomaRenal InsufficiencySolid Tumors
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RecruitingNCT06179160
Start: 2024-01-04End: 2027-01-01Target: 710Updated: 2026-07-22
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
CompletedNCT07018635
Start: 2025-07-16End: 2025-09-29Updated: 2025-11-26
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants
Active, not recruitingNCT07814404
Start: 2026-09-18End: 2026-10-15Updated: 2026-10-14
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
Not yet recruitingNCT07853040
Start: 2026-10-13End: 2027-03-31Target: 24Updated: 2026-10-01
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
Not yet recruitingNCT07854249
Start: 2026-10-26End: 2027-03-30Target: 24Updated: 2026-10-02
Phase 3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingNCT07522073
Start: 2026-04-09End: 2029-03-19Target: 588Updated: 2026-10-08
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Not yet recruitingCTIS2025-525009-18-00
Target: 71Updated: 2026-06-29